Health Care

Antitrust and Competition Policy in the Health Care Industry

Antitrust and Competition Policy in the Health Care Industry

NERA's experience in health care antitrust goes beyond the realm of hospitals, health insurers, physicians, and pharmaceutical companies. NERA economists have also been retained to analyze a variety of medical products and industries, such as home health care and ambulance services. Our health care economics practice predates the recent burst of activity in the field by over a decade, and our experience in providing analysis and expert testimony on competitive effects, alleged price fixing, price discrimination, and other antitrust issues is a cornerstone of our practice.
 
NERA economists advise clients on issues related to market definition, entry conditions, pricing conduct, exclusionary behavior, predation, and profitability. We participate in all stages of pre-transaction counseling and analysis of antitrust risks. We advise companies and their attorneys, as well as governments and regulators, on monopoly and market dominance/abuse of market power investigations throughout the world. NERA advises on issues related to allegations of foreclosure, tying, excessive pricing, refusals to deal, essential facilities, and predatory pricing. We also work on cases involving alleged anti-competitive agreements, including issues raised by claims of vertical restraints and the economic impact of franchising and cartel activity. We consult with clients at all phases of the Hart-Scott Rodino notification process, including making presentations to lawyers and economists at the DOJ and FTC.

Name Title Location Phone Email
Dr. Graeme Hunter Senior Managing Director New York City +1 212 345 7724 graeme.hunter@nera.com
James Mellsop Senior Managing Director
Chair of NERA's Global Antitrust and Competition Practice
Auckland
Wellington
Sydney
+64 9 928 3290
+64 4 819 2550
+61 2 8864 6536
james.mellsop@nera.com
Dr. Christine Siegwarth Meyer Senior Managing Director White Plains, NY +1 914 448 4119 christine.meyer@nera.com
Dr. Subramaniam (Subbu) Ramanarayanan Senior Managing Director New York City
Los Angeles
+1 212 345 0745
+1 213 346 3038
subbu.ramanarayanan@nera.com
Dr. Ramsey Shehadeh Senior Managing Director Washington, DC +1 212 345 6089 ramsey.shehadeh@nera.com
Dr. Elizabeth Newlon Managing Director Los Angeles +1 213 346 3019 elizabeth.newlon@nera.com
Dr. Paul Wong Managing Director San Francisco +1 415 291 1030 paul.wong@nera.com
Kevin Counsell Director Wellington
Sydney
+64 4 819 2551
+61 2 8864 7235
kevin.counsell@nera.com
Dr. Garrett Glasgow Director San Francisco +1 415 291 1029 garrett.glasgow@nera.com
Dr. Emily Walden Director Washington, DC +1 202 466 9220 emily.walden@nera.com
Brigid Jung Senior Consultant New York City +1 212 345 7039 brigid.jung@nera.com
Dr. Michael Baye Affiliated Academic Washington, DC +1 202 466 9298 michael.baye.affiliate@nera.com
Dr. Alyssa Lutz Affiliated Consultant Los Angeles +1 714 545 3000 alyssa.lutz@nera.com
Dr. Thomas McCarthy Affiliated Consultant Los Angeles +1 213 346 3000 thomas.mccarthy.affiliate@nera.com
Title Type Author
The Algorithmic Accountability Act: Potential Coverage Gaps in the Healthcare Sector Published Article Dr. Andrew Stivers and Dr. Gabriella Monahova
The Role of Rebates in the Pharmaceutical Industry Published Article Dr. Chris Stomberg
Non-Compete Agreements: Might They Be Procompetitive in Health Care? Published Article Dr. Paul Wong and Dr. Emily Walden
Drug Rebates: A Peek Behind the Curtain at Drug Prices Published Article Dr. Christopher Stomberg
Taking Stock of the Efficiencies Defense: Lessons from Recent Health Care Merger Revi... Published Article Dr. Subramaniam Ramanarayanan
Reduced-Form Versus Structural Econometric Methods in Market Definition: Lessons from... Published Article Dr. Subbu Ramanarayanan and Dr. Paul Wong
Paper Trail: Review of a Recent Working Paper on the Effect of Copay Coupons on Drug ... Published Article Bryan Ray and Dr. Subbu Ramanarayanan
A Profile of Professor Martin S. Gaynor (Director, FTC Bureau of Economics) Published Article By Dr. Subramaniam (Subbu) Ramanarayanan
An Inside Look at Monopsony Issues in the FTC's Express Scripts-Medco Merger Investig... Published Article By John Scalf with Rani Habash of Dechert LLP
Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development E... Working Paper By Dr. Graeme Hunter with Dr. John Vernon and Dr. Joseph Cook